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Abstract: Recent evidence suggests that gut microbiota shifts can alter host metabolism even during
healthy aging. Lactobacillus acidophilus DDS-1, a probiotic strain, has shown promising probiotic
character in vitro, as well as in clinical studies. The present study was carried out to investigate
whether DDS-1 can modulate the host metabolic phenotype under the condition of age-affected gut
microbial shifts in young and aging C57BL/6J mice. Collected fecal samples were analyzed using
16S rRNA gene sequencing for identifying gut microbiota and untargeted gas chromatography-mass
spectrometry (GC-MS) metabolomics analysis. Gut microbial shifts were observed in the control
groups (young and aging), leading to an alteration in metabolism. Principal coordinate analysis
(PCoA) of microbiota indicated distinct separation in both the DDS-1-treated groups. L. acidophilus
DDS-1 increased the relative abundances of beneficial bacteria, such as Akkermansia muciniphila and
Lactobacillus spp., and reduced the relative levels of opportunistic bacteria such as Proteobacteria spp.
Metabolic pathway analysis identified 10 key pathways involving amino acid metabolism, protein
synthesis and metabolism, carbohydrate metabolism, and butanoate metabolism. These findings
suggest that modulation of gut microbiota by DDS-1 results in improvement of metabolic phenotype
in the aging mice.
Keywords: aging; gut microbiota; metabolism; probiotics
1. Introduction
Microbes residing in a mammalian gut co-evolve with age. These microbes, known as the
‘gut microbiota’, interact with each other, as well as the host, and impact the health of the host [1].
Alterations in gut microbial communities are known to not only influence but also act as a possible
causative factor for various gastrointestinal (GI) and metabolic disorders [1–3]. Apart from antibiotics,
diet, and environmental factors, the age of the host is also linked with the gut microbial changes [2,4,5].
Recently, human and animal studies have reported microbial shifts in aging gut under healthy
conditions [1–3,5]. From these studies, it is known that Bacteroidetes and Firmicutes, which dominate in
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younger individuals, are being reduced with the age [2,4,6]. In addition, the abundance of beneficial
bacteria, such as Akkermansia spp. and Lactobacillus spp., were reduced in the aging population [7–9].
Such drastic microbial shifts in healthy-aging could lead to increased intestinal inflammation and
changes in host metabolism.
Along these lines, a few animal and clinical studies demonstrated metabolic trajectory associated
with gut microbiome upon aging [10–13]. Primarily, these studies indicated alterations in levels
of metabolites involved in the metabolism of amino acids, carbohydrates, nucleotides, lipid, and
short-chain fatty acids (SCFA) in the aging group compared to the young group, leading from normal
to putrefactive metabolism [10,14,15]. Given the potential for gut microbiota to change with age and
its influence on host metabolism, modulation of gut microbial composition offers an opportunity
to promote digestive health among the aging population. A number of studies have demonstrated
that the lactic acid bacteria (LAB) probiotic strains, especially Lactobacillus spp., are natural, safe, and
beneficial modulators of the gut microbial composition and metabolic phenotype [16–18]. Indeed,
clinical studies have shown that supplementation of Lactobacillus strains improved the overall health
in elderly individuals [17,19–23].
Previously, we showed that DDS-1 strain has a promising ability to survive under stressed
conditions (pH, salts, and digestive enzymes), colonize in the gut, and modulate the immune
system [18]. Clinically, the DDS-1 strain has alleviated the symptoms associated with lactose intolerance
in healthy volunteers between 18 to 75 years of age [24]. In addition, this particular probiotic strain has
reduced symptoms of atopic dermatitis by improving immune markers and significantly shortened
acute respiratory tract infection [25–27]. However, there are no studies on DDS-1 evaluating its capacity
to alter the microbiota and metabolic phenotypes. The above-mentioned studies [18,24,27] encouraged
us to hypothesize that the probiotic strain, L. acidophilus DDS-1, could further improve the beneficial
microbial composition of healthy gut and host metabolism. Precise identification of metabolites
associated with DDS-1 treatment throughout aging will be beneficial to identify disease-modifying,
clinically accessible biomarkers for host health [28].
In the current study, we employed a healthy aging-based model to evaluate the direct effects
of DDS-1 on gut microbiota changes associated with fecal metabolome composition. A combination
of omics-based approaches, involving 16S rRNA gene sequencing and untargeted GC-MS based
metabolomics, were utilized to provide a comprehensive understanding of changes in host metabolic
phenotype of altering gut microbiota with and without DDS-1 supplementation.
2. Methods
2.1. Ethics Statement
All animal procedures were performed in accordance with the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes of the National Health and Medical Research Council.
The study was approved by the Animal Ethics Committee of the University of Tasmania (A0015840).
2.2. Bacterial Culture and Probiotic Feed Preparation
The bacterial strain utilized in the study, L. acidophilus DDS-1, was obtained in freeze-dried,
free-flowing lyophilized form from UAS Labs, Madison, WI, USA. The bacterial culture was suspended
in autoclaved water before making the probiotic-chow mix at a concentration of approximately
3 × 109 CFU/g in a manner similar to Kuo et al. [29].
2.3. Animals and Probiotic Treatments
A total of 32 mice were used in the present study. Young (age = 3–4 weeks, n = 16) and
aging (age = 35–36 weeks, n = 16) C57BL/6J mice of both sexes were obtained from the University
of Tasmania animal breeding facility. Animals were housed within individually ventilated cages
containing a corncob bedding (Andersons, Maumee, OH, USA), in a room with a temperature
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maintained at 21–22 ◦C, with a 12-h light/dark cycle. Mice were allowed access to radiation-sterilized
rodent feed (Barastoc Rat and Mouse (102108), Ridley Agriproducts, Melbourne, Australia) and water
available ad libitum. The young and aging mice were randomly divided into 4 groups (n = 8) and
housed in individual cages containing (1) Young control group (YC) fed with normal chow, (2) Young
probiotic group (YP) fed with probiotic chow, (3) Aging control group (AC) fed with normal chow,
and (4) Aging probiotic group (AP) fed with probiotic chow. All the mice were fed for 4 weeks with
group-specific chow
2.4. Fecal Sample Collection and Preparation
Throughout the experiment, the weight of each mouse was recorded each day and fecal samples
were collected on the 28th day in a manner similar to Langille et al. [2]. To minimize contamination,
on the day of sampling mice had no access to food and water, and sterile forceps were used for fecal
sample collection. At least 2 pellets (100–150 mg of the sample) were collected from each mouse
and immediately transferred into a sterile microcentrifuge tube, stored at −80 ◦C for 16S rRNA gene
sequencing and metabolomic analysis.
2.5. Microbiota Analysis Using 16S rRNA High-Throughput Sequencing
The total DNA was extracted from fecal samples using the QIAamp DNA Stool Mini Kit (Qiagen,
Melbourne, VIC, Australia). The samples underwent high-throughput sequencing on the Illumina
MiSeq platform at the Australian Genome Research Facility (University of Queensland, Brisbane,
QLD, Australia). PCR amplicons spanning the 16S rRNA V3-V4 hypervariable region with forward
Primer (27F) AGAGTTTGATCMTGGCTCAG and reverse Primer (519R) GWATTACCGCGGCKGCTG
were sequenced. Paired-end reads were assembled by aligning the forward and reverse reads using
PEAR1 (version 0.9.5) [30]. Primers were identified and trimmed. Trimmed sequences were processed
using Quantitative Insights into Microbial Ecology (QIIME 1.8) 4 USEARCH 2.3 (version 8.0.1623)
and UPARSE software [31]. Using USEARCH tools, sequences were quality filtered, and full-length
duplicate sequences were removed and sorted by abundance. Singletons or unique reads in the data
set were discarded. Sequences were clustered followed by chimera filtered using “rdp_gold” database
as a reference [32,33]. To obtain a number of reads in each Operational taxonomic units (OTUs), reads
were mapped back to OTUs with a minimum identity of 97%. Using QIIME, taxonomy was assigned
using Greengenes database5 (Version 13_8, August 2013). Image analysis was performed in real time
by the MiSeq Control Software (MCS) v2.6.2.1 and Real-Time Analysis (RTA) v1.18.54, running on the
instrument computer. RTA performs real-time base calling on the MiSeq instrument computer. Then the
Illumina bcl2fastq 2.20.0.422 pipeline [32] was used to generate the sequence data. Next, 16S rRNA gene
sequences were analyzed using MEGAN6 (Community edition version) [34], Microbiome analyst [35],
and QIIME. Statistical analysis of Brady-Curtis dissimilarities calculated using the relative abundances
of bacterial genera was conducted using Adonis function in R (version 3.2).
2.6. Fecal Metabolomics
The samples were subjected to derivatisation to increase volatility before subjecting to GC-MS
analysis. Briefly, fecal samples (n = 5, weight = 40 mg) were freeze-dried and suspended in 1 mL
methanol (LC-MS grade, Merck, Castle Hill, NSW, Australia), supplemented with 10 µg/mL adonitol
(Analytical grade, Sigma Aldrich, Castle Hill, NSW, Australia) as an internal standard in a sterile 2 mL
bead-beating tube. The samples were homogenized by bead beating for 30 s and then centrifuged
at 570 g/4 ◦C for 15 min. The supernatant (50 µL) was transferred to a fresh centrifuge tube
(1.5 mL) and dried in a vacuum evaporator centrifuge (LabGear, Brisbane, QLD, Australia) at 35 ◦C.
Methoxyamine-HCl (20 mg/mL in Pyridine) (both, Analytical grade, Sigma Aldrich, Castle Hill, NSW,
Australia) was added (40 µL) and samples were incubated at 30 ◦C/ 1400 rpm (ThermoMixer C,
Eppendorf, Hamburg, Germany) for 90 min. This was followed by silylation with 70 µL BSTFA at
37 ◦C/1400 rpm for 30 min. Pre-derivatized 13C-Stearic acid (10 µg/mL) was added (1 µL) as the
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QA/QC internal standard. The mixture was briefly vortexed and centrifuged at 15,700 g for 5 min.
The aliquot was transferred to vials for GC-MS analysis.
The GC-MS analysis was performed on an Agilent 6890B gas chromatograph (GC) oven coupled to
a 5977B mass spectrometer (MS) detector (Agilent Technologies, Mulgrave, VIC, Australia) fitted with
a MPS autosampler (Gerstel GmbH & Co. KG, Deutschland, Germany). The GC-MS conditions were as
stated previously [36–38]. Data acquisition and spectral analysis were performed using the Qualitative
Analysis software (Version B.08.00) of MassHunter workstation. Qualitative identification of the
compounds was performed according to the Metabolomics Standard Initiative (MSI) chemical analysis
workgroup [39] using standard GC-MS reference metabolite libraries (NIST 17, Fiehn Metabolomics
RTL Library (G166766A, Agilent Technologies) and the Golm database) and with the use of Kovats
retention indices based on a reference n-alkane standard (C8-C40 Alkanes Calibration Standard,
Sigma-Aldrich, Castle Hill, NSW, Australia). For peak integration, a 5-point detection filtering (default
settings) was set with a start threshold of 0.2 and a stop threshold of 0.0 for 10 scans per sample.
Procedural blanks (n = 7) were analyzed randomly throughout the sequence batch. The obtained
data was processed on Quantitative analysis platform of MassHunter workstation and exported as a
Microsoft Excel output file for statistical analysis.
2.7. Data Analysis and Multivariate Analysis
GC-MS data imported to Microsoft Excel platform was normalized with respect to the internal
standard adonitol (relative standard deviation = 11.257%). The normalized data was further
log-transformed and auto-scaled (mean-centered) before statistical analysis [40]. To determine
overall microbial variation in four groups, we used a principal coordinate analysis (PCoA),
Unweighted Pair Group Method with Arithmetic Mean (UPGMA) dendrogram, Neighbour-Net
(a distance-based method for constructing phylogenetic networks) hierarchical clustering with
Brady-Curtis ecological indexing, Euclidean distances as the similarity measure, and Ward’s linkage
as clustering algorithm [3,40]. For analysis of metabolome variations, Principal component analysis
(PCA), partial least squares-discriminant analysis (PLS-DA) and orthogonal (O) PLS-DA were used.
Because PLS-DA can overfit data, we used 1000 permutations to validate these models. The OPLS-DA
was used to identify discrimination between metabolites contributing to classification. For heatmaps,
the Euclidean distances were used as the similarity measure and Ward’s linkage as a clustering
algorithm. Metabolite set enrichment analysis (MSEA) and Metabolic pathway analysis (MetPA)
methods were used to perform correlation analysis and to identify treatment associated biochemical
pathways [41].
2.8. Statistical Analysis
Graph Pad Prism version 7.0 for Windows was used for the statistical analysis. The data were
analyzed using the Wilcoxon Mann–Whitney Test (multiple comparisons), with p < 0.05 set as the
level of statistical significance. For microbial comparative analysis, a linear discriminant effect size
(LEfSe) analysis was performed (α = 0.05), logarithmic Linear Discriminant Analysis (LDA) score
threshold = 1.0. A MetaboAnalyst (Version 4.0) data annotation approach and Kyoto Encyclopaedia
of Genes and Genomes (KEGG) Pathway Database were used for the hierarchical clustering analysis
and significance analysis for microarrays (SAM), along with the variable importance of projection
(VIP) [42]. The SAM and VIP methods are well-established statistical methods for metabolites and
were used to select the most discriminant and interesting biomarkers [43].
3. Results
3.1. Body Weight During Days of Treatments
There was no significant change in body weights of mice treated with DDS-1 (Figure 1).
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Figure 1. Effect of DDS-1 supplementation on body weights among the four groups. (YC) Young 
control group, (YP) young probiotic group, (AC) aging control group, (AP) aging probiotic group. 
3.2. Gut Microbial Changes at the Phylum Level 
Fecal microbiota profiling was performed using 16S rRNA gene sequencing-based method. To 
compare the changes among the groups, PCoA was used. The PCoA plot of phylogeny with Brady-
Curtis ecological indexing using ward clustering showed a clear separation of each group, with three 
distinct clusters (Figure 2A) at the OTU level among 4 groups. After DDS-1 treatment, both AP and 
YP groups segregated when compared to control groups. Particularly, the AP group more 
significantly separated from AC as depicted in UPGMA hierarchical clustering dendrogram (p < 0.01) 
(Figure 2B) and Neighbour-Net (Figure S1). Moreover, around 99% of the total microbial abundance 
was classified into nine major phyla in the aging group and seven in the young group, the rest were 
allocated as unclassified or others (Figure 2C). The dominant phyla were Bacteroidetes and Firmicutes, 
with their numbers higher in the young group (86.46 ± 2.10% and 8.20 ± 1.20%) compared with the 
aging group (63.35 ± 3.10% and 26.33 ± 4.45%) (p < 0.001). 
The treatment with DDS-1 helped increased Firmicutes levels from 8.40% to 9.32% (YP) (p < 0.001) 
and 26.33% to 30.72% (AP) (p < 0.001). However, it decreased the levels of Bacteroidetes in both the 
groups, reflecting the effect of DDS-1 supplementation on overall abundance of Firmicutes. 
Verrucomicrobia abundance was significantly increased in both treatment groups (YP: 0.72% to 2.10%; 
AP: 0.62 to 4.20%) (p < 0.001). Proteobacteria levels were decreased from 1.70% to 0.58% in the aging 
group after DDS-1 treatment. These changes in the aging groups were further confirmed with LEfSe 
analysis (α = 0.05), LDA approach keeping the cut-off value for p = 0.01 and log LDA threshold score 
= 1.0 (Figure 3A). In addition, under phylum Bacteroidetes, the relatively novel family S24-7 were 
overrepresented in both the control groups (YC: 70.30% and AC: 52.8%) and their relative abundances 
were further decreased with DDS-1 treatment (YC: 67.50% and AC: 50.8%). Overall correlation 
analysis was performed using Spearman correlation analysis (Figure S2) with p < 0.01 as significant.
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3.2. Gut Microbial Changes at the Phylum Level
Fecal microbiota profiling was performed using 16S rRNA gene sequencing-based method.
To compare the changes among the groups, PCoA was used. The PCoA plot of phylogeny with
Brady-Curtis ecological indexing using ward clustering showed a clear separation of each group,
with three distinct clusters (Figure 2A) at the OTU level among 4 groups. After DDS-1 treatment,
both AP and YP groups segregated when compared to control groups. Particularly, the AP group more
significantly separated from AC as depicted in UPGMA hierarchical clustering dendrogram (p < 0.01)
(Figure 2B) and Neighbour-Net (Figure S1). Moreover, around 99% of the total microbial abundance
was classified into nine major phyla in the aging group and seven in the young group, the rest were
allocated as unclassified or others (Figure 2C). The dominant phyla were Bacteroidetes and Firmicutes,
with their numbers higher in the young group (86.46 ± 2.10% and 8.20 ± 1.20%) compared with the
aging group (63.35 ± 3.10% and 26.33 ± 4.45%) (p < 0.001).
The treatment with DDS-1 helped increased Firmicutes levels from 8.40% to 9.32% (YP) (p < 0.001)
and 26.33% to 30.72% (AP) (p < 0.001). However, it decreased the levels of Bacteroidetes in both
the groups, reflecting the effect of DDS-1 supplementation on overall abundance of Firmicutes.
Verrucomicrobia abundance was significantly increased in both treatment groups (YP: 0.72% to 2.10%;
AP: 0.62 to 4.20%) (p < 0.001). Proteobacteria levels were decreased from 1.70% to 0.58% in the aging
group after DDS-1 treatment. These changes in the aging groups were further confirmed with LEfSe
analysis (α = 0.05), LDA approach keeping the cut-off value for p = 0.01 and log LDA threshold
score = 1.0 (Figure 3A). In addition, under phylum Bacteroidetes, the relatively novel family S24-7 were
overrepresented in both the control groups (YC: 70.30% and AC: 52.8%) and their relative abundances
were further decreased with DDS-1 treatment (YC: 67.50% and AC: 50.8%). Overall correlation analysis
was performed using Spearman correlation analysis (Figure S2) with p < 0.01 as significant.
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Figure 2. The gut microbiota changes observed in young control group (YC), young probiotic group
(YP), aging control group (AC), aging probiotic group (AP) differentiated by principal coordinate
analysis (PCoA) (A) and UPMGA dendrogram (B). The gut microbiota composition profiles at phylum
(C) and genus levels (D) in control and probiotic-treated group, revealed by 16S rRNA gene sequencing
(each color represents bacterial phylum and/or genus).
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Figure 3. Comparative analysis with Linear Discriminant Analysis (LDA) E fect Size (LEfSe) scoring
plot sing Krusk l-Wa lis rank u test (p 0.01 and log threshold cut-o f alue 1.0). Aging
groups at Phylum (A) nd ge u (B) l vel. Young groups at genus ( ) level. Significant changes at
species (D) level. (YC) Youn control group, (YP) young robiotic group, (AC) a ing control group,
(AP) aging probiotic group.
3.3. Gut Microbial Changes at Genus and Species Level Among Four Groups
At the genus level, the distribution of microbial populations of the aging groups was markedly
different from the young groups. The AC group had significantly higher abundances of Staphylococcus,
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Ruminococcus, and Sutterella relative to the AP group. The DDS-1 treatment has increased the
abundances of Akkermansia, Adlercreutzia, Allobaculum, Rikenella, and Anaeroplasma, while reduced the
abundances of Dorea, Oscillospira, and Ruminococcus (Figure 2D). It is noteworthy that the Lactobacillus
(p < 0.001) abundances significantly increase in AP group and was further confirmed with the
LDA approach (Figure 3B). At the species level, DDS-1 treated groups have significantly increased
A. muciniphila (p < 0.001) and decreased levels of R. gnavus, Bacteroides acidifaciences, and B. uniformis
compared to the AC group (Figure 3D). Adding to this change, an abundance of Mucispirillum schaedleri
(0.04 ± 0.02% to 0.10 ± 0.06%) was also increased in the AP group.
The YC group was enriched with Prevotella, Ruminococcus, and Sutterella, while very low levels
of Adlercreutzia, Allobaculum, and Alphaproteobacteria, were identified compared to the AC group.
Anaeroplasma and Staphylococcus were totally absent compared to the AC group. The treatment with
DDS-1 increased the levels of Akkermansia (p < 0.05), Parabacteroides, and Odoribacter (Figure 2D).
It also further increased Prevotella and Sutterella levels (p < 0.05) and was confirmed using the LDA
approach (Figure 3C) in YP group. Similar to AP group, at the species level in YP group, A. muciniphila
(p < 0.001) levels were considerably increased, and R. gnavus, Bacteroides acidifaciences, and B. uniformis
levels were decreased compared to the YC group (Figure 3D). Certain bacterial species, such as M.
schaedleri, were undetected in young groups. The beneficial effects of DDS-1 on modulating the gut
microbiota were found to have a differential effect in between the two age groups. The treatment with
DDS-1 significantly altered AP group, which was evident with the higher levels of Lactobacillus in
fecal samples.
3.4. Metabolic Phenotyping of YC and YP Groups
To gain an untargeted overview of probiotic-induced changes in dominant gut metabolites,
we analyzed fecal samples using a GC-MS platform. A total of 68 metabolites of different functional
groups such as sugars, amino acids, SCFAs, and biogenic amines were detected. An unsupervised
PCA was used to obtain an overview of the samples, and all samples were clearly discriminated, as
shown in Figure 4A. PCA analysis showed a distinct clustering of the control group and DDS-1 treated
group fecal samples. The biplot for PC1 and PC2 showed the compounds with the greatest impact
on the division among the samples, as shown in Figure 4B. In order to provide a better visualization
and to carry out the class separating information of each variable, a supervised PLS-DA approach was
used to evaluate the metabolic patterns of YC group and YP group (Figure 4C). This analysis indicated
the clear differences in the metabolic profiles of mice in YP and YC groups, which suggests that DDS-1
treatment induced significant biochemical changes. The accuracy, R2X, R2Y and Q2 of PLS-DA score
analysis were 0.9, 0.86, and 0.82, respectively (Figure 4C), indicating the classification was well suited
for the models, and the control and treated groups were classified clearly.
3.5. Identification of Potential Fecal Metabolites Associated with the YP/YC Groups
The supervised orthogonal PLS-DA (OPLS-DA) was employed to further enhance the observed
group separation in PCA and PLS-DA. Combination of PCA, PLS-DA, and VIP scores and O-PLS-DA
(R2Y = 0.993 (p = 0.01), Q2 = 0.811 (p = 0.01)) (Figure S3A) and SAM enabled us to identify potential
biomarkers (Figure 5A). The metabolites with VIP score > 1 and SAM (Figure 5A) could be considered
as potential biomarkers responsible for altering the metabolic profile post DDS-1 treatment. The results
showed 36 statistically significant metabolites contributing to the clustering, with their SAM scores
and KEGG, InChI Key IDs listed in Table S1. Of the confirmed identifications, the most significant
compounds were 4-Guanidinobutanoic acid (Fold changes (FC) = 149.21, p = 0.0055), Iminodiacetic
acid (FC = 75.57, p = 0.022), L-Aspartic acid (FC = 47.02, p = 0.002), and L-Proline (FC = 31.96, p = 0.001).
The varied tendencies of the identified fecal metabolites post DDS-1 treatment are depicted in the heat
map (Figure 5B). Finally, the number of markers making a significant contribution was 21 in positive
mode and 15 in negative mode using SAM and VIP analysis, as shown in Figure 4D.
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.6. M tabolic Phenotypi g of AC and AP Groups
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s such as sugars, ami o acids, SCFAs, a d biogenic amines. The PCA and PLS-DA models
were performed to evaluate the metabolic phenotyping of the AC group nd AP group (Figure 6A,C).
The biplot for PC1 and PC2 showed th compounds with the greatest impact on the ivisi among
the samples, as shown in Figure 6B. The metabolic profile f mice in the AP group differ d from
the AC group, indic ing significant bioch mical changes induced by DDS-1. The accuracy, R2Y,
and Q2 of PLS-DA score analysis were 0.763, 0.959, and 0.824, r spectively (Figure 6C), i dicating the
classifi tions was well suit d for the models, and the control an tre ted groups were classified clearly.
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3.7. Identification of Potential Fecal Metabolites Associated with the AP/AC Groups
The supervised OPLS-DA model was utilized to enhance the biomarker identification.
The OPLS-DA method separated the control group and probiotic group into two different blocks,
indicating better discrimination (R2Y= 0.994 (p = 0.01), Q2 = 0.863(p = 0.1)) (Figure S3B). From VIP
scores (Figure 6D), PCA, PLS-DA, and O-PLS-DA approach, we could identify a total of 19 statistically
significant metabolites that contribute to the overall cluster (Table S2). Out of identified 19 significantly
changed metabolites in feces, 7 compounds were selected as potential biomarkers involved in the
classification of AP gut using SAM analysis (Delta value = 0.5) (Figure 7A). Of the confirmed
identifications, the most significant compounds were Lactose (Fold changes (FC) = 3.16, p = 0.003),
Melibiose (FC = 3.13, p = 0.04), Cellobiose (FC = 3.06, p = 0.02). The varied tendencies of the identified
fecal metabolites post DDS-1are depicted in the heat map for each group (Figure 7B).Nutrients 2018, 10, x FOR PEER REVIEW  19 of 20 
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3.8. Comparative Metabolite Phenotyping in Young and Aging Groups
PCA and PLS-DA analyses of the fecal metabolites showed a divergence between all four groups
(Figure 8A,B). The samples from YC and AC were different from YP and AP groups, respectively
(Figure S4A–D). Fecal samples from the groups YC and YP formed two clusters. Both of the clusters
from the young groups were different and showed great divergence compared to the aging groups.
Similarly, the AP group formed a cluster which was fairly different from the AC group and more closely
related to the YP group (Figure 8B). The bi-plot for PC1 and PC2 shows the variation in the dataset
and indicates that specific metabolites associated with the four groups are responsible for divergence
among the samples (Figure S5A). VIP-value plot (Figure S5B) of the most significant metabolites and
Figures S5–S8 presents heat map correlation analysis, showing the relative concentrations of significant
metabolites in all four groups.
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3.9. Identification of Key Metabolic Pathways Using MetPA
Detailed analysis of functional correlations and networks influenced throughout aging and with
DDS-1 supplementation were performed by MetPA and MSEA methods. In order to identify the
pathways that had an impact on altering gut microbiota-associated metabolic signature, the ions
contributing to the separation of controls and probiotic-supplemented mice were analyzed using
MetPA, MetaboAnalyst 4.0 (http://www.metaboanalyst.ca) [40,42]. A comprehensive metabolic
network was mapped using joint pathway analysis by integration of all potential biomarkers identified
in the current research.
In the young group, metabolic pathway analysis revealed that the metabolites which were
identified as significant are important for host response to DDS-1 treatment (Figure 9A and Table S3).
An impact value was set to 0.10 as a threshold, and any pathway receiving > 0.10 value was filtered
out as potential target pathways [3,28,40–42]. These pathways include Valine, leucine, and isoleucine
biosynthesis, Alanine, aspartate, and glutamate metabolism, Pentose and glucuronate interconversions,
Aminoacyl-tRNA biosynthesis, Glycine, serine, and threonine metabolism, Galactose metabolism,
and Cysteine and methionine metabolism. In the aging groups, a total of 5 metabolic pathways were
identified (impact > 0.10) (Figure 9B and Table S4). D-glutamine and D-glutamate metabolism, alanine,
aspartate and glutamate metabolism, galactose metabolism, nitrogen metabolism, and butanoate
metabolism were recognized as key pathways in DDS-1-induced changes in metabolic phenotype of the
aging gut. Omics Net was used to select and isolate individual KEGGS-genome-metabolite mapping
(http://www.omicsnet.ca) [40,42] (Figures S9–S13). Of all the pathways identified, two pathways were
found to be common among both age groups, specifically galactose metabolism and alanine, aspartate,
and glutamate metabolism. These two pathways may play a role in the ability of LAB probiotics to
modulate host metabolism via gut microbiota.
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4. Discussion
In our study, we used a combination of 16S rRNA sequencing analysis and untargeted
metabolomics profiling of fecal samples to identify specific gut microbiota changes and numerous
gut metabolites that were associated with response to DDS-1 supplementation in young and aging
mice. Importantly, DDS-1 increased Firmicutes abundance and enriched the populations of Akkermansia
and Lactobacillus. Metabolic profiling of fecal samples indicated substantial changes to metabolites
generated by gut microbes. Specifically, DDS-1 improved metabolism of pathways associated with
amino acids, proteins, and carbohydrates.
Taxonomic differences were evaluated in this study among young and aging groups with and
without DDS-1 treatment. In line with previous findings, our study confirms a microbial shift in the
aging mouse gut [2,5,44]. At the phylum level, Bacteroidetes and Firmicutes were most dominant and
their relative abundances were increased in the YC group compared to the AC group. Acidobacteria
and Tenericutes were not detected in the young groups. DDS-1 treatment increased the Firmicutes
population in both YP and AP groups, reflecting the role of Lactobacillus in overall abundance [2].
It is noteworthy that Verrucomicrobia levels were also significantly increased with DDS-1 treatment.
Furthermore, Proteobacteria levels, which have been associated with inflammatory bowel disease (IBD)
and colon cancer [4,16,45], were doubled in AC relative to the YC group. DDS-1 treatment was able
to reduce their levels, indicating a potentially beneficial role as it relates to controlling intestinal
inflammation [18,24,29]. Importantly, more than 50% of the mouse gut was enriched with a relatively
new family S-24-7, that belongs to Bacteroidetes phylum. Only a few studies could hypothesize the role
of S-24-7 in butyrate production, however, the results were inconclusive and further research should
be performed to understand its role [6,46].
We observed noticeable changes at the genus and species level within the aging mice groups.
Interestingly, our data found an increase in abundance of A. muciniphila and Lactobacillus with DDS-1
treatment specific to the aging gut, which is consistent with previous studies [8,17,47]. Increase in
relative abundance of the phylum Firmicutes could be associated with an increase of beneficial bacterial
species, such as Lactobacillus species [16]. The mucin-feeding species, A. muciniphila, are thought to
be biomarkers of intestinal health and their enrichment has been inversely correlated with IBD and
metabolic disorders [2,16,44]. Recently, a study on aging obese mice demonstrated the extracellular
vesicles of A. muciniphila improved body weight and lipid profiles of the mice concomitantly with
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metformin treatment [47]. In several prior studies, animals treated with A. muciniphila reported
improvements in body weight, metabolic profiles, inflammation, and overall gut homeostasis by
influencing immunity, mucin-layer thickness, and intestinal epithelial barrier proteins [1,44,47]. This was
consistent with changes observed in body weights of the mice treated with DDS-1 in our study.
Moreover, in our study, the levels of Allobaculum were increased in mice fed with DDS-1. Interestingly,
the major end products of Allobaculum fermentation is butyrate (SCFA), which serves as a primary
energy source in the gut [9]. In addition, bacterial species such as R. gnavus were present in both YC
and AC groups. This particular member of Clostridia was directly correlated with the severity of IBD,
suggesting its causal role in a dysbiotic shift in the aging gut [48]. DDS-1 supplementation was able to
decrease R. gnavus abundance, and thus could possibly reduce inflammation associated with IBD or
other conditions [18,24,26,27,48].
The small molecules present in feces are products of co-metabolism of microbes and host cells.
Therefore, metabolite profiling in feces provides insight on novel metabolic biomarkers for health [3,28].
In an attempt to gain functional insight into changes in the gut microbiome, we have used a functional
pathway analysis on probiotic-treated gut microbiota-derived metabolites. Untargeted metabolite
profiling of control groups and DDS-1 supplemented groups not only allowed us to identify specific
metabolites in the young and aging gut, but also to understand the mechanistic role of DDS-1.
Our analysis revealed varying levels of metabolites in young and aging mice. The metabolite profile in
the YC group was dissimilar from the AC group, which could be correlated with microbial shift [2,4,5].
Interestingly, we found that the metabolic phenotype of AP mice was clustered more towards YP mice
(Figure 7B). The DDS-1 treatment allowed us to identify specific metabolites and their pathway-specific
expressions profiles which demonstrated changes in metabolism are discussed below [41,49].
4.1. Amino Acid and Protein Metabolism
In many metabolic pathways, amino acids serve as crucial regulatory substrates [50]. Fecal
branched-chain amino acids (BCAAs) such as valine, leucine, and isoleucine were significantly
down-regulated in the YP group compared to the YC group. In particular, increases in a small cluster
of essential amino acids including the BCAAs (i.e., leucine, valine, and isoleucine) are associated with
a ~5-fold increased the risk of prospectively developing diabetes mellitus [3,6,41]. On the other hand,
Clostridium, Propionibacterium, Fusobacterium, Streptococcus, and Lactobacillus bacteria are involved in the
proteolytic activity to generate amino acids in the gut and linked to metabolic changes [49]. Specifically,
altered levels of Streptococcus have been associated with metabolic disorders[6]. In our study, the
relative abundance of Streptococcus is decreased in probiotic-treated groups. Moreover, glycine, serine,
and threonine metabolism was increased in the YP group. This could be associated with decreased
levels of L-serine in YP and AP, and these changes could be positively correlated with Proteobacteria
and Prevotella, and negatively correlated with Bacteroides [3,51].
Glutamine, another nonessential amino acid and a precursor of glutamate, is able to promote
beta-cells to secrete insulin under the stimulation of glucose. Glutamate, which can be converted into
gamma-aminobutyric acid (GABA), is of vital importance in the decomposition of metabolites [52].
In addition, glutamate can also be converted into ornithine. On the other hand, aspartate can be
transformed into asparagine and alanine. A study by Wang et al. [41] reported that elevated levels of
alanine and aspartate have a positive association with obesity. In our study, the levels of alanine and
aspartate were significantly decreased in the feces of the AP group, indicating a potentially beneficial
role of DDS-1 in aging, which can be positively correlated with an increase in levels of A. muciniphila.
In addition, the aging process can have a profound effect on protein metabolism, as well as overall
nutritional status influenced by food intake [53,54]. Therefore, our results speculate that alanine,
aspartate, and glutamate metabolism post-enrichment of A. muciniphila may potentially reduce the
risk factors of metabolic syndrome.
Cysteine and methionine are the only two sulfur-containing amino acids that integrate
into proteins [55]. Accumulating evidence indicates that the intestinal metabolism of dietary
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sulfur-containing amino acids methionine and cysteine are nutritionally important for normal intestinal
mucosal growth [56]. The cysteine and methionine metabolism pathway was upregulated in YP group,
which could be associated with beneficial modulation of gut microbiota and basic metabolism of
growth in youth [55]. Our MetPA analysis indicated that L-serine, with importance score of 0.07407,
was equally involved in the pathway. Studies have reported the role of the LAB, such as Lactobacillus
species, in the biosynthesis of cysteine from serine, suggesting the role of DDS-1. In particular, this
could be positively correlated with decreased levels of Desulfovibrionales in DDS-1 treated groups,
which are associated with bacterial infections and Crohn’s disease [16].
Aminoacyl-tRNA (A-tRNA) plays a vital role in RNA translation (tRNA) and gene expression
associated with protein biosynthesis [57]. Amino-acylation of tRNA involves A-tRNA synthetases to
catalyze and form an association between cognate amino acid and tRNA, which is the initial step of
protein synthesis. This involves in adenylation of amino acid to A-tRNA in adenosine triphosphate
(ATP)-dependent manner to form Aminoacyl-adenosine monophosphate (AMP). This is followed by
formation of A-tRNA and AMP in presence of A-AMP. In turn, an accurate A-tRNA biosynthesis is
required for survival of all cells [58]. In addition, specific aminoacyl tRNA synthetases are implicated
in various metabolic and neurological disorders [59]. Specifically, tetracyclines, a class of antibiotics,
interfere with the initiation step of protein synthesis by inhibiting the binding of aminoacyl tRNA to
the A-site of the ribosome, leading to bacteriostatic effect [60]. The activation of A-tRNA biosynthesis
pathway could be an important factor in amino acid metabolism and activation of other amino acid
pathways mentioned above [61]. It is noteworthy that A-tRNA biosynthesis pathway was only
detected in the YP group. In particular, MetPA indicated that L-aspartic acid, L-serine, L-valine,
L-lysine, L-threonine, and Isoleucine, with importance scores ≥ 0.02, were significantly involved in
this pathway. The altered levels of the above-mentioned amino acids in YP were well correlated with
the beneficial role of DDS-1 in protein synthesis and metabolism.
Nitrogen balance is an essential part of protein metabolism. The biological process of the nitrogen
cycle is a complex interplay among many gut microbes catalyzing different reactions, where nitrogen
is found in various oxidation states ranging from +5 in nitrate to −3 in ammonia [62]. Nitrogen
metabolism pathway was only activated in the AP group when compared with the AC group.
This could be linked to activation of amino acid metabolism, majorly, D-Glutamine and D-glutamate
metabolism, where Glutamine (importance score = 0.11) can serve as a nitrogen donor in the production
of amino sugars, nucleotides, and other amino acids [54,63]. Thus, glutamate/glutamine and aspartate
are also associated with nitrogen metabolism (Figure S12B). On the other hand, removing amino acid
nitrogen from the body is known as transaminations [64]. Transaminations are a class of reactions
which helps in dissociation of nitrogen from amino acids either by deamination or oxidation process
into a small group of compounds [65]. This result in ammonia production and their amine groups are
converted to urea by the urea cycle [66]. Here, we used the total amount of urea present in the feces as
a factor to measure nitrogen metabolism. Increased concentration of urea in the AP group indicates
that DDS-1 has a regulatory effect on nitrogen metabolism perturbation [67].
4.2. Carbohydrate Metabolism
Digestion of lactose produces glucose and galactose, both of which are transported through the
hepatic portal vein directly to the liver [54]. Galactose is metabolized by conversion initially to glucose
1-phosphate, which can then be converted either to glucose 6-phosphate or to glycogen. Galactose
is crucial for human metabolism, with an established role in energy delivery and galactosylation of
complex molecules [68]. Its main metabolic pathway is highly conserved in nature, being present in
all living organisms. In humans, galactose is particularly important in early development. Genetic
disorders that impair its metabolism inevitably cause disease, drawing attention to its key role [69].
Excess of galactose accumulation in tissue leads to various metabolic disorders. According to our
MetPA analysis, metabolites such as D-galactose, melibiose, and lactose are shown to be directly
involved in the D-galactose pathway. In our study, levels of these three metabolites were decreased
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in both YP and AP, which is directly correlated to active galactose metabolism demonstrating the
beneficial role of DDS-1. Specifically, this could be correlated with increased in beneficial bacteria, such
as Akkermansia species following probiotic treatment [3,17].
4.3. Butanoate Metabolism
The detailed functional analysis using MetPA analysis in our study indicated the importance of
L-glutamic acid and oxoglutaric acid in Butanoate metabolism. Oxoglutaric levels were increased in
AP when compared to AC. Butanoate or butyrate is a short chain fatty acid and secondary metabolite
produced by gut microbes upon carbohydrate fermentation [7]. Although it was not detected in the
untargeted metabolomics, butanoate (SCFA) could be linked to increased butyrate-producing bacteria
in the gut. Bacteria classified under Firmicutes are directly involved in the Butanoate production [41].
In turn, SCFA act as a critical energy source for intestinal epithelial cells. Butanoate metabolism
pathway activation in AP could be linked to increased relative abundances of Firmicutes, especially
increased levels of Lactobacillus. A. muciniphila and Allobaculum enrichment in treatment groups is also
positively correlated with SCFA production [16]. The DDS-1 treatment significantly ameliorated and
modulated the gut microbiota associated metabolic pathways.
To the best of our knowledge, this is the first detailed study that demonstrates an integrated
pattern recognition approach to understand the changes in the aging gut by exploring the metabolic
network with and without probiotic supplementation. The key metabolic pathways identified by
MetPA and MSEA play an important role in probiotic-induced gut microbiota-associated metabolic
changes. Understanding the complex nature of specific gut microbiome and metabolome of the
mouse, our study corroborates previous findings of gut microbiota shifts in aging could result in
significant alterations in metabolic phenotype of the host with relevance to human health [2,5,47,54].
Any specific change to metabolic phenotype may lead to various GI and metabolic disorders [17,53,54].
The current model of probiotic-induced gut microbial and metabolic profiling is largely explained by a
multi-omics approach using fecal 16S rRNA sequencing analysis and metabolomics [70]. Our results
suggest that the aging-associated shifts in gut microbiota can be modulated by the dietary intervention
of L. acidophilus DDS-1. In particular, this intervention enriched a number of beneficial bacteria,
such as Akkermansia, Allobaculum, and Lactobacillus spp. in the gut, and directly contributed to the
improvement of the host metabolic phenotype [8]. Translation of these outcomes to clinical accessibility
warrants furthers larger mouse cohorts with extreme older mice before clinical studies. Indeed, DDS-1
intervention intended to selectively promote bacteria could become a vital dietary strategy to counteract
aging-associated dysbiosis.
5. Conclusions
Our results highlight the key role of beneficial microbes/probiotics in determining and modulating
the metabolic profile in the healthy-aging gut. Similar approaches could be used as a reference to
identify and target specific health-promoting metabolic pathways in young and aging populations.
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(YP) from Figure 8A (A) Valine, leucine and isoleucine biosynthesis, (B) Glycine, serine and threonine metabolism,
(C) Aminoacyl-tRNA biosynthesis. Compounds in red are significantly involved in the pathways, Figure S10:
Potential pathways for Aging probiotic (AP) from Figure 8B, (A) D-Glutamine and D-glutamate metabolism (B)
Alanine, aspartate and glutamate metabolism (C) Nitrogen metabolism, (D) Butanoate metabolism. Compounds in
red are significantly involved in the pathways, Figure S11: KEGGS pathways of Alanine, aspartate and glutamate
metabolism (A) and Galactose Metabolism (B). Compounds highlighted in red and green are directly involved
in respective pathways, Figure S12: KEGGS pathways of Butanoate metabolism (A) and Nitrogen Metabolism
(B). Compounds highlighted in red box and green are directly involved in respective pathways, Table S1: Most
significant compounds identified in YP/YC groups, Table S2: Most significant compounds identified by OPLS-DA
and SAM analysis in AP group. (*First 7 compounds are identified by SAM).
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